Sirs, Increased serum prolactin (PRL) levels have been demonstrated in several autoimmune diseases including polymyositis (PM) and systemic sclerosis (SSc) [1] [2] [3] . PRL is produced by the lactotrophs of the pituitary gland, but the immune cells can produce PRL as well, and PRL acts as a cytokine with role in B, T, and dendritic cell maturation [1] . Czuwara-Ladykowska et al.
[4] demonstrated higher PRL mRNA synthesis in lymphocytes from patients suVering from SSc than in healthy individuals. Multiple promoters regulate PRL gene transcription. Unlike the pituitary production controlled by the pituitary promoter under the inXuence of transcriptional factor Pit-1, the extrapituitary (including that by immune cells) PRL secretion is regulated by the Pit-1 independent alternative promoter located 5840 bp distal to the start of the PRL transcriptional site [5] . This extrapituitary promoter contains functional single nucleotide polymorphism (SNP) ¡1149 G/T (rs1341239) in the GATA sequence; G allele leads to higher PRL mRNA in lymphocytes synthesis [6] . GG genotype has been associated with systemic lupus erythematosus (SLE) [6, 7] , while TT genotype was identiWed as protective for non-Hodgkin and follicular lymphoma, and rheumatoid arthritis development [8, 9] .
In this study, we looked for distribution of allele and genotype of the ¡1149 G/T SNP of the extrapituitary PRL promoter in 75 patients with SSc (average age 61.4), in 47 subjects with PM (average age 57.8), in 68 patients with dermatomyositis (DM) (average age 58.3), and in 123 healthy Czech individuals (blood donors and medical students, average age 39.7). SSc and PM/DM patients met classiWcation criteria for these illnesses [10, 11] . PCR-RFLP methodology was used for ¡1149G/T SNP detection [7] . BrieXy, we ampliWed 137 bp region of the PRL extrapituitary promoter and for restriction used ApoI endonuclease. We determined the following genotypes: the homozygote TT characterized by 120 + 17 bp, the homozygote GG by 85 + 35 + 17 bp, and the heterozygote GT by 120 + 85 + 35 + 17 bp DNA fragments. Results were evaluated by 2 test with Bonferroni correction. Control group was in Hardy-Weinberg equilibrium.
The genotype and allele distribution did not show any signiWcant diVerences in groups of PM, DM, and SSc patients compared to healthy individuals (Table 1) , and we detected neither gender distribution diVerences (data not shown) nor correlation with speciWc clinical or serological manifestation of these diseases (lung Wbrosis, type of scleroderma, antiScl-70 and antiJo-1 positivity) (Table 1) . However, we found a signiWcant inverse association between TT genotype in SSc patients with disease onset after 45 years compared to individuals with SSc and diseases onset prior to 45 years (2/47 = 4.1 vs. 6/18 = 25%, respectively; P corrected = 0.02; OR = 0.13; CI (95%): 0.02-0.69).
Thus, genotype ¡1149 TT of the extrapituitary PRL promoter SNP (via reduced PRL promoter activity and consequently lower PRL levels in lymphocytes) seems to be associated with decreased risk to SSc development in older age. With regards to the age of onset, no diferences in allele or genotype frequences in patients with polymyositis and dermatomyositis were found. We can assume that this polymorphism might be somewhat speciWc for SSc and therefore warrants further investigation into PRL genetics and its levels during the disease course. 
